These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6420161)

  • 1. Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
    ten Berge RJ; Schellekens PT; Hamerlynck JV; Bruning PF
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):91-8. PubMed ID: 6420161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
    Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
    Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Vermorken JB; van Lindert AC; Heintz AP; Aartsen E; van Lent M
    Eur J Cancer; 1991; 27(11):1367-72. PubMed ID: 1835850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
    Kohorn EI; Klein-Angerer S
    Gynecol Oncol; 1984 Sep; 19(1):60-6. PubMed ID: 6432636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 14. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
    Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
    Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altretamine.
    Hansen LA; Hughes TE
    DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
    Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
    Lund B; Hansen M; Hansen HH; Thomsen HK; Sørensen BL; Nielsen NC; Lundvall F
    Ann Oncol; 1990; 1(2):134-40. PubMed ID: 2127690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Richman CM; Podczaski E; Weiser PA; Herbst AL
    Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Pinedo HM
    Radiother Oncol; 1984 Jun; 2(1):19-29. PubMed ID: 6438704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.